Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 6:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 48 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Pioglitazone 15 mg Clear all
Terminated Phase 4 Interventional Results available

Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

NCT03471117
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Pioglitazone, Placebo
Drug · Other
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
35 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Arlington, Texas • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 15, 2026, 6:43 AM EDT
Terminated Phase 2 Interventional Results available

Insulin Resistance in Pulmonary Arterial Hypertension

NCT00825266
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
bosentan, Pioglitazone
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Sep 15, 2026, 6:43 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function

NCT00845182
View directory record Official record
Conditions
Type 2 Diabetes, Healthy, Impaired Glucose Tolerance
Interventions
Pioglitazone, Exenatide, Pioglitazone and Exenatide
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Sep 15, 2026, 6:43 AM EDT
Active, not recruiting Phase 4 Interventional

Dapagliflozin Plus Pioglitazone in T1DM

NCT03878459
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Pioglitazone 45 mg, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 15, 2026, 6:43 AM EDT
Completed Phase 1 Interventional

Effect of Pioglitazone on Inflammation in Cystic Fibrosis

NCT00719381
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Pioglitazone
Drug
Lead sponsor
Paul Beringer
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2012 · Synced Sep 15, 2026, 6:43 AM EDT
Terminated Phase 4 Interventional Results available

Pioglitazone for the Treatment of Bipolar Depression

NCT01717040
View directory record Official record
Conditions
Bipolar Disorder, Insulin Resistance
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Sep 15, 2026, 6:43 AM EDT
Terminated Phase 3 Interventional

GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus

NCT00226330
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Tesaglitazar, Pioglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
110
States / cities
Birmingham, Alabama • Columbiana, Alabama • Mobile, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2010 · Synced Sep 15, 2026, 6:43 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus

NCT00762736
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone and azilsartan, Pioglitazone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
704 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
64
States / cities
Birmingham, Alabama • Huntsville, Alabama • Sierra Vista, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Sep 15, 2026, 6:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Skeletal Muscle Dysfunction in Rheumatoid Arthritis (RA)

NCT02535832
View directory record Official record
Conditions
Rheumatoid Arthritis, Insulin Resistance
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
Ohio State University
Other
Eligibility
35 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 26, 2023 · Synced Sep 15, 2026, 6:43 AM EDT
Completed Phase 2 Interventional Results available

Treating Nonalcoholic Steatohepatitis With Pioglitazone

NCT00062764
View directory record Official record
Conditions
Hepatitis
Interventions
Actos (Pioglitazone)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Sep 15, 2026, 6:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s

NCT03457597
View directory record Official record
Conditions
Healthy
Interventions
Midazolam hydrochloride, Metoprolol tartrate, Pioglitazone hydrochloride, Tolbutamide, Omeprazole, Relacorilant
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Sep 15, 2026, 6:43 AM EDT
Terminated Phase 2 Interventional Results available

Pioglitazone for Oral Premalignant Lesions

NCT00951379
View directory record Official record
Conditions
Oral Leukoplakia
Interventions
Pioglitazone hydrochloride, placebo, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
11
States / cities
Birmingham, Alabama • Iowa City, Iowa • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced Sep 15, 2026, 6:43 AM EDT
Completed Phase 3 Interventional Results available

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

NCT01183013
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Pioglitazone 15 mg, Pioglitazone 45 mg, Pioglitazone 30 mg, Linagliptin 5mg / Pioglitazone 45 mg FDC, Linagliptin 5mg / Pioglitazone 30 mg FDC, Linagliptin 5mg, Linagliptin 5mg / Pioglitazone 15 mg FDC
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
936 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
74
States / cities
Birmingham, Alabama • Montgomery, Alabama • Muscle Shoals, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2014 · Synced Sep 15, 2026, 6:43 AM EDT
Completed Phase 2 Interventional Results available

Pioglitazone in Early Parkinson's Disease

NCT01280123
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Pioglitazone, placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
30 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Sep 15, 2026, 6:43 AM EDT
Recruiting Phase 3 Interventional

Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

NCT06246799
View directory record Official record
Conditions
Type 2 Diabetes (Adult Onset)
Interventions
Tirzepatide, Pioglitazone, Sitagliptin, Metformin HCI XR
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 75 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 15, 2026, 6:43 AM EDT
Recruiting Phase 1 Interventional

SGLT2i, Pioglitazone, and Ketone Production in T2D

NCT07053319
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Empagliflozin 25 MG, Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin Placebo, Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d)
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
30 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 15, 2026, 6:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991)

NCT02222441
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib alone, Palbociclib plus Modafinil, Palbociclib plus pioglitazone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 19, 2015 · Synced Sep 15, 2026, 6:43 AM EDT
Completed Phase 1 Interventional

Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis

NCT03231033
View directory record Official record
Conditions
Autoimmune Pulmonary Alveolar Proteinosis
Interventions
Pioglitazone
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 15, 2026, 6:43 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

NCT02969798
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG)
Interventions
Dapagliflozin, Saxagliptin, Pioglitazone, Metformin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 15, 2026, 6:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of MGL-3196 With Pioglitazone

NCT04671056
View directory record Official record
Conditions
Healthy
Interventions
MGL-3196, Pioglitazone 15mg
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 15, 2026, 6:43 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone

NCT01395784
View directory record Official record
Conditions
Opioid Abuse
Interventions
pioglitazone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Sep 15, 2026, 6:43 AM EDT
Completed Phase 3 Interventional

Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.

NCT00225264
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone, Glimepiride
Drug
Lead sponsor
Takeda
Industry
Eligibility
45 Years to 85 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Sep 15, 2026, 6:43 AM EDT
Completed Phase 4 Interventional

Pioglitazone Incretin Study

NCT00656864
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
South Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 1, 2011 · Synced Sep 15, 2026, 6:43 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

DPP-4 Inhibition and TZD for DM Prevention

NCT01006018
View directory record Official record
Conditions
Prediabetic State
Interventions
Sitagliptin + Pioglitazone PLACEBO, Sitagliptin + Pioglitazone, PLACEBO
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Sep 15, 2026, 6:43 AM EDT